keyword
MENU ▼
Read by QxMD icon Read
search

Cancer methylphenidate

keyword
https://www.readbyqxmd.com/read/29208618/feasibility-study-of-a-randomised-controlled-trial-to-investigate-the-treatment-of-sarcoidosis-associated-fatigue-with-methylphenidate-fast-mp-a-study-protocol
#1
Christopher Atkins, Richard Fordham, Allan B Clark, Andrea Stockl, Andrew P Jones, Andrew M Wilson
INTRODUCTION: Fatigue is a frequent and troublesome manifestation of chronic sarcoidosis. This symptom can be debilitating and difficult to treat, with poor response to the treatment. Symptomatic management with neurostimulants, such as methylphenidate, is a possible treatment option. The use of such treatment strategies is not without precedent and has been trialled in cancer-related fatigue. Their use in sarcoidosis requires further evaluation before it can be recommended for clinical practice...
December 4, 2017: BMJ Open
https://www.readbyqxmd.com/read/28947882/the-problem-of-fatigue-in-patients-suffering-from-neoplastic-disease
#2
REVIEW
Agnieszka Kolak, Marzena Kamińska, Elwira Wysokińska, Dariusz Surdyka, Dariusz Kieszko, Magdalena Pakieła, Franciszek Burdan
Modern therapeutic management of patients with cancer is associated with many adverse side effects, including fatigue defined as weariness, burnout, lassitude, malaise, apathy, impatience, and/or inability to perform daily activities. It occurs frequently before the diagnosis of cancer and may persist for a long time after the end of cancer therapy. It is a common problem that occurs regardless of the type of cancer and applied therapeutic procedure. The appearance of this symptom significantly affects the quality of life of patients and often reduces the effectiveness of implemented treatment...
2017: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/28885263/the-use-of-methylphenidate-to-relieve-fatigue
#3
Rocío Rojí, Carlos Centeno
PURPOSE OF REVIEW: To review recent evidence on the efficacy and safety of methylphenidate as a symptomatic treatment of patients with cancer-related fatigue (CRF). RECENT FINDINGS: Five clinical trials published since 2011 were identified. Two of these concluded that methylphenidate is more efficacious than placebo in providing relief from CRF, but the remaining three showed no difference in favour of methylphenidate. The studies were heterogeneous as per the dosage, scales used for evaluating fatigue and the target group studied...
December 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28700116/an-integrative-literature-review-exploring-the-clinical-management-of-delirium-in-patients-with-advanced-cancer
#4
REVIEW
Hayley Lawley, Alistair Hewison
AIM: The aim of this paper is to present the findings of an integrative literature review of the evidence for the clinical management of delirium in patients with advanced cancer. BACKGROUND: Patients with advanced cancer frequently experience delirium which can be distressing for both patients and their families. Current guidelines recommend that underlying causes of the delirium be addressed and a course of antipsychotics considered. However the research into the effectiveness of treatments for delirium in people with advanced cancer is limited...
July 12, 2017: Journal of Clinical Nursing
https://www.readbyqxmd.com/read/28322161/the-use-of-methylphenidate-in-cancer-patients-a-review
#5
Beatrice Andrew, Chong Guan Ng, Nik Ruzyanei Nik Jaafar
BACKGROUND: One of the goals of cancer treatment is symptoms management especially at the end stage. The common symptoms in cancer include pain, fatigue, depression and cognitive dysfunction. The available treatment options for symptom management are limited. Methylphenidate, a psychostimulant, may be of benefit for these patients. In this report, we review the use of methylphenidate for symptoms control in cancer patients. METHOD: Electronic literature search on PubMed was conducted using the following keywords: methylphenidate, cancer, carcinoma, oncology, oncological and tumour...
March 17, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28299946/single-institute-experience-with-methylphenidate-and-american-ginseng-in-cancer-related-fatigue
#6
Young D Chang, Joshua Smith, Diane Portman, Richard Kim, Ritika Oberoi-Jassal, Sahana Rajasekhara, Mellar Davis
BACKGROUND: Single therapy with methylphenidate or American ginseng contributes to the reduction in cancer-related fatigue (CRF) with different pharmacologic mechanisms and is relatively safe. However, the safety and efficacy of treating CRF with methylphenidate and AG combination therapy is unknown. AIM: The primary objective was to assess the clinical safety and the change in fatigue with numerical rating scale (NRS) on the Edmonton Symptom Assessment Scale (ESAS) after intervention with methylphenidate and AG combination therapy...
January 1, 2017: American Journal of Hospice & Palliative Care
https://www.readbyqxmd.com/read/28156680/the-combination-therapy-with-methylphenidate-and-american-ginseng-in-cancer-related-fatigue
#7
Joshua Smith, Diane G Portman, Ritika Oberoi-Jassal, Sahana Rajasekhara, Mellar P Davis
215 Background: Fatigue is one of common symptoms among patients with cancer. However, little is known about the pathophysiology and effective pharmacologic intervention. Methylphenidate and American Ginseng were recognized for promising results and safe to use as a single therapy. Psycho-stimulants are commonly used and are effective in moderate to severe fatigue. The mechanism behind the evidence for methylphenidate is rebalancing dopamine neurotransmission which is altered in fatigue. The mechanism behind ginseng benefits appears to be improvement in muscle metabolism and reduction in inflammatory responses thought to cause fatigue in cancer...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28006939/the-effect-of-combined-treatment-of-opioids-with-methylphenidate-on-nociception-in-rats-and-pain-in-human
#8
A Yamamotová, J Fricová, R Rokyta, R Šlamberová
Methylphenidate hydrochloride (MPH/Ritalin) is a stimulant used for off-label management of cancer-related fatigue and sedation; however, its use in pain treatment is still relatively rare. This study 1) compares the antinociceptive effect of MPH and its combination with morphine (MOR) in adult male Wistar rats after a single administration of MPH, MOR or their combination, and 2) compares the analgesic effects of opioids and Ritalin combined therapy with opioid monotherapy in patients with cancer pain. To objectively assess physical activity during a three-week monitoring period, patients were equipped with Actiwatch Score Actigraph...
December 22, 2016: Physiological Research
https://www.readbyqxmd.com/read/27708523/role-of-methylphenidate-in-the-treatment-of-fatigue-in-advanced-pancreatic-cancer-population
#9
Zhenyang Jiang, Harriet Butler-Bowen, Teresa Rodriguez, Marie C Garcon, Melissa Hennessey Smith, Valerie Relias, Muhammad Wasif Saif
BACKGROUND: Fatigue is a common but devastating symptom for advanced pancreatic cancer (APC) patients. To date, no proven treatment exists. Methylphenidate (MPH) showed inconsistent results in treating other cancer related fatigue. We performed a retrospective study to assess MPH in ameliorating fatigue in APC patients. METHODS: We retrospectively reviewed our clinic APC patients' records who visited from 06/2011 - 11/2014. Fatigue was assessed by Visual Analog Fatigue Scale (VAFS) and classified as grade 1 (VAFS 1-3), grade 2 (VAFS 4-6) and grade 3 (VAFS 7-10) to correspond with CTCAE V4...
October 2016: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/27429350/randomized-double-blind-placebo-controlled-study-of-methylphenidate-for-the-treatment-of-depression-in-ssri-treated-cancer-patients-receiving-palliative-care
#10
Donald R Sullivan, Solange Mongoue-Tchokote, Motomi Mori, Elizabeth Goy, Linda Ganzini
OBJECTIVE: To determine the effectiveness of methylphenidate for depression treatment in patients with advanced cancer. DESIGN: An 18-day randomized, double-blind, placebo-controlled clinical trial of methylphenidate for treatment of depression in selective serotonin reuptake inhibitor-treated patients with advanced cancer in hospice or receiving palliative care. The primary outcome was depression remission, defined as a ≥50% reduction in score on the Montgomery-Asberg Depression Rating Scale...
November 2017: Psycho-oncology
https://www.readbyqxmd.com/read/27066315/pharmacological-treatments-for-fatigue-associated-with-palliative-care-executive-summary-of-a-cochrane-collaboration-systematic-review
#11
REVIEW
Martin Mücke, Mochamat, Henning Cuhls, Vera Peuckmann-Post, Ollie Minton, Patrick Stone, Lukas Radbruch
BACKGROUND: In palliative care patients, fatigue can be severely debilitating and is often not counteracted with rest, thereby impacting daily activity and quality of life. Further complicating issues are the multidimensionality, subjective nature and lack of a consensus definition of fatigue. The review aimed to evaluate the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases...
March 2016: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/26918390/interventions-for-cognitive-deficits-in-breast-cancer-survivors-treated-with-chemotherapy
#12
REVIEW
David E Vance, Jennifer Sandson Frank, Jennifer Bail, Kristen L Triebel, Lindsay M Niccolai, Adam Gerstenecker, Karen Meneses
BACKGROUND: Cognitive deficits are distressing adverse effects of chemotherapy that have a negative effect on quality of life in breast cancer survivors (BCSs). Cognitive deficits in cancer survivors are a top research and clinical practice priority. OBJECTIVE: The aims of this study were to describe cognitive deficits that occur after chemotherapy, describe deficits in BCSs treated with chemotherapy within a framework of cognitive reserve and neuroplasticity, and discuss cognitive interventions (ie, cognitive training interventions, compensatory strategies with cognitive training interventions, pharmacological interventions, and complementary and integrative medicine interventions)...
January 2017: Cancer Nursing
https://www.readbyqxmd.com/read/26490083/psychotropic-drugs-for-the-management-of-cancer-related-fatigue-a-systematic-review-and-meta-analysis
#13
REVIEW
D Qu, Z Zhang, X Yu, J Zhao, F Qiu, J Huang
Cancer-related fatigue (CRF) is a common symptom affecting 60-90% of cancer survivors, and effective management for CRF is not yet available. Recently, an increasing number of trials examining the use of psychotropic drugs for the treatment of CRF have been performed, but these trials have yielded inconsistent results. Therefore, we conducted a meta-analysis aimed at assessing the effect and safety of psychotropic drugs for the management of CRF. Ten eligible trials of the psychotropic drugs methylphenidate and modafinil in a total of 1582 participants treated for CRF were subjected to statistical analyses...
November 2016: European Journal of Cancer Care
https://www.readbyqxmd.com/read/26469939/suppression-of-locomotor-activity-in-female-c57bl-6j-mice-treated-with-interleukin-1%C3%AE-investigating-a-method-for-the-study-of-fatigue-in-laboratory-animals
#14
David R Bonsall, Hyunji Kim, Catherine Tocci, Awa Ndiaye, Abbey Petronzio, Grace McKay-Corkum, Penny C Molyneux, Thomas E Scammell, Mary E Harrington
Fatigue is a disabling symptom in patients with multiple sclerosis and Parkinson's Disease, and is also common in patients with traumatic brain injury, cancer, and inflammatory disorders. Little is known about the neurobiology of fatigue, in part due to the lack of an approach to induce fatigue in laboratory animals. Fatigue is a common response to systemic challenge by pathogens, a response in part mediated through action of the pro-inflammatory cytokine interleukin-1 beta (IL-1β). We investigated the behavioral responses of mice to IL-1β...
2015: PloS One
https://www.readbyqxmd.com/read/26254017/the-role-of-methylphenidate-in-cancer-related-fatigue-commentary-on-mitchell-et%C3%A2-al
#15
COMMENT
Eduardo Bruera
No abstract text is available yet for this article.
September 2015: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/26026155/pharmacological-treatments-for-fatigue-associated-with-palliative-care
#16
REVIEW
Martin Mücke, Henning Cuhls, Vera Peuckmann-Post, Ollie Minton, Patrick Stone, Lukas Radbruch
BACKGROUND: This review updates the original review, 'Pharmacological treatments for fatigue associated with palliative care' and also incorporates the review 'Drug therapy for the management of cancer-related fatigue'.In healthy individuals, fatigue is a protective response to physical or mental stress, often relieved by rest. By contrast, in palliative care patients' fatigue can be severely debilitating and is often not counteracted with rest, thereby impacting daily activity and quality of life...
May 30, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/25896104/the-effect-of-methylphenidate-on-fatigue-in-advanced-cancer-an-aggregated-n-of-1-trial
#17
RANDOMIZED CONTROLLED TRIAL
Geoffrey K Mitchell, Janet R Hardy, Catherine J Nikles, Sue-Ann S Carmont, Hugh E Senior, Philip J Schluter, Phillip Good, David C Currow
CONTEXT: Fatigue is common in life-limiting cancer. Methylphenidate (MPH), a psychostimulant, may be a useful therapy. Gathering evidence in patients with advanced cancer can be challenging. OBJECTIVES: To determine if MPH improves cancer-related fatigue in people with advanced cancer. METHODS: N-of-1 trials are multicycle, double-blind, randomized, controlled crossover trials using standardized measures of effect in individuals. They are normally used to assess treatment effects in individuals...
September 2015: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/25299141/review-of-clinical-trials-of-pharmacologic-interventions-for-cancer-related-fatigue-focus-on-psychostimulants-and-steroids
#18
REVIEW
Sriram Yennurajalingam, Eduardo Bruera
Cancer-related fatigue (CRF) is the most common and debilitating symptom in patients with cancer. Currently, there are very limited pharmacological interventions to effectively treat CRF. In this article, the authors review various pharmacological interventions for CRF and propose future direction for further research. Methylphenidate is the most studied pharmacological agent for the treatment of CRF. Various pharmacological studies have suggested benefit of corticosteroids, especially in terminally ill patients for a short period...
September 2014: Cancer Journal
https://www.readbyqxmd.com/read/25080574/developing-interventions-for-cancer-related-cognitive-dysfunction-in-childhood-cancer-survivors
#19
REVIEW
Sharon M Castellino, Nicole J Ullrich, Megan J Whelen, Beverly J Lange
Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck. Risk factors for cancer-related cognitive dysfunction include young age at diagnosis, treatment with cranial irradiation, use of parenteral or intrathecal methotrexate, female sex, and pre-existing comorbidities. Limiting use and reducing doses and volume of cranial irradiation while intensifying chemotherapy have improved survival and reduced the severity of cognitive dysfunction, especially in leukemia...
August 2014: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/24994918/survivorship-cognitive-function-version-1-2014
#20
Crystal S Denlinger, Jennifer A Ligibel, Madhuri Are, K Scott Baker, Wendy Demark-Wahnefried, Debra L Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H Ku, Elizabeth Kvale, Terry S Langbaum, Kristin Leonardi-Warren, Mary S McCabe, Michelle Melisko, Jose G Montoya, Kathi Mooney, Mary Ann Morgan, Javid J Moslehi, Tracey O'Connor, Linda Overholser, Electra D Paskett, Muhammad Raza, Karen L Syrjala, Susan G Urba, Mark T Wakabayashi, Phyllis Zee, Nicole R McMillian, Deborah A Freedman-Cass
Cognitive impairment is a common complaint among cancer survivors and may be a consequence of the tumors themselves or direct effects of cancer-related treatment (eg, chemotherapy, endocrine therapy, radiation). For some survivors, symptoms persist over the long term and, when more severe, can impact quality of life and function. This section of the NCCN Guidelines for Survivorship provides assessment, evaluation, and management recommendations for cognitive dysfunction in survivors. Nonpharmacologic interventions (eg, instruction in coping strategies; management of distress, pain, sleep disturbances, and fatigue; occupational therapy) are recommended, with pharmacologic interventions as a last line of therapy in survivors for whom other interventions have been insufficient...
July 2014: Journal of the National Comprehensive Cancer Network: JNCCN
keyword
keyword
108623
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"